君实生物午后涨超10% PD-(L)1/VEGF赛道景气度提高机构称JS207具备BD潜力

智通财经2025-07-04

君实生物(01877)午后涨超10% ，截至发稿，涨9.17%，报26.2港元，成交额4.52亿港元。消息面上，近期，由君实生物自主研发的重组人源化抗PD-1和VEGF双特异性抗体JS207的抗肿瘤作用机制及临床前研究结果在国际知名学术期刊《Frontiers in Immunology》上全文发表，详细描绘了JS207的分子设计、体外特征、功能和临床前抗肿瘤疗效。方正证券指出，JS207(PD1...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2548354306?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-04 14:08","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2548354306","market":"us","top_or_hot":-1,"title":"君实生物午后涨超10% PD-(L)1/VEGF赛道景气度提高 机构称JS207具备BD潜力","media":"智通财经","content":"<div>\n<p>君实生物(01877)午后涨超10% ，截至发稿，涨9.17%，报26.2港元，成交额4.52亿港元。消息面上，近期，由君实生物自主研发的重组人源化抗PD-1和VEGF双特异性抗体JS207的抗肿瘤作用机制及临床前研究结果在国际知名学术期刊《Frontiers in Immunology》上全文发表，详细描绘了JS207的分子设计、体外特征、功能和临床前抗肿瘤疗效。方正证券指出，JS207(PD1...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704141501a4cecd56&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>君实生物午后涨超10% PD-(L)1/VEGF赛道景气度提高 机构称JS207具备BD潜力</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n君实生物午后涨超10% PD-(L)1/VEGF赛道景气度提高 机构称JS207具备BD潜力\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-04 14:08 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704141501a4cecd56&s=b><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>君实生物(01877)午后涨超10% ，截至发稿，涨9.17%，报26.2港元，成交额4.52亿港元。消息面上，近期，由君实生物自主研发的重组人源化抗PD-1和VEGF双特异性抗体JS207的抗肿瘤作用机制及临床前研究结果在国际知名学术期刊《Frontiers in Immunology》上全文发表，详细描绘了JS207的分子设计、体外特征、功能和临床前抗肿瘤疗效。方正证券指出，JS207(PD1...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704141501a4cecd56&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0203345920.USD","symbol_name":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704141501a4cecd56&s=b","article_id":"2548354306","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704141501a4cecd56&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2548354306","pubTimestamp":1751609284,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"君实生物午后涨超10% ，截至发稿，涨9.17%，报26.2港元，成交额4.52亿港元。方正证券指出，JS207临床前数据发表，展现二代PD1抗肿瘤潜力。该行认为，JS207具备BD潜力。而仍有MNC未布局二代PD1产品，JS207具有BD潜力。截至2025年5月，MNC中仅辉瑞和默沙东通过引进布局此赛道，后续随着数据的不断成熟及联合应用潜力的不断验证，中国其他早期PD-1/VEGF双抗也将有机会BD出海。目前PD-1/VEGF双抗赛道景气度不断提高，相关标的有望持续受益。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688180":"君实生物","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","LU1069347547.HKD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (HKD) INC","LU0861579265.USD":"联博低波幅策略股票基金A","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU1917777945.USD":"安联专题基金Cl AT Acc","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","L":"洛斯公司","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","SG9999014559.SGD":"United Income Focus Trust Dis SGD","BK4588":"碎股","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","PFE":"辉瑞","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU0122379950.USD":"贝莱德世界健康科学A2","PD":"PagerDuty, Inc.","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","01877":"君实生物","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","MRK":"默沙东","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC"},"translate_title":"Junshi Biotech rose more than 10% in the afternoon PD-(L) 1/VEGF track prosperity improved. Institutions say JS207 has BD potential","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688180":0.9,"PFE":0.9,"01877":0.9,"PD":1,"L":1,"MRK":0.9},"content_text":"君实生物(01877)午后涨超10% ，截至发稿，涨9.17%，报26.2港元，成交额4.52亿港元。消息面上，近期，由君实生物自主研发的重组人源化抗PD-1和VEGF双特异性抗体JS207的抗肿瘤作用机制及临床前研究结果在国际知名学术期刊《Frontiers in Immunology》上全文发表，详细描绘了JS207的分子设计、体外特征、功能和临床前抗肿瘤疗效。方正证券指出，JS207(PD1/VEGFA双抗)临床前数据发表，展现二代PD1抗肿瘤潜力。该行认为，JS207具备BD潜力。海外药企看重PD1/VEGF 的大药潜力，纷纷引入中国PD1/VEGF 产品，Summit、biontech、默沙东、辉瑞、Instil 分别引进康方、普米斯、礼新、三生、宜明昂科的PD1(L1)/VEGF(R)的双抗。而仍有MNC未布局二代PD1产品，JS207具有BD潜力。此外，有报道称，阿斯利康与Summit正在商谈AK112药物合作事宜，合作金额高达150亿美元。开源证券此前指，PD-(L)1/VEGF双抗作为有望迭代PD-(L)1单抗市场的下一代IO基石药物，后续与ADC/TCE等联用将持续拓宽市场空间。截至2025年5月，MNC中仅辉瑞和默沙东通过引进布局此赛道，后续随着数据的不断成熟及联合应用潜力的不断验证，中国其他早期PD-(L)1/VEGF双抗也将有机会BD出海。目前PD-(L)1/VEGF双抗赛道景气度不断提高，相关标的有望持续受益。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2548354306","isCrawlerRequest":true}

君实生物午后涨超10% PD-(L)1/VEGF赛道景气度提高 机构称JS207具备BD潜力

精彩评论

君实生物午后涨超10% PD-(L)1/VEGF赛道景气度提高机构称JS207具备BD潜力